Association of Lipid Mediators of Inflammation with TB Treatment Outcomes

Post Date: 
Clinical Sites: 

This study was terminated July 22, 2019.

This study used stored samples from the Cohort for Tuberculosis Research by the Indo-US Medical Partnership (C-TRIUMPH), under the Regional Prospective Observational Research for Tuberculosis (RePORT) Network, an international TB consortium.

Recent studies have shown the significant role that host lipids play in modulating immunity and disease outcomes. Prostaglandins and leukotrienes are lipids that have a pro-inflammatory role in the fight against infectious agents while Specialized Pro-resolving lipid Mediators (SPMs) including resolvins, protectins and maresins, are important for the effective resolution of inflammation(1-3). In TB, there is evidence of a delicate balance where an excess of either the pro-inflammatory LTB4 or pro-resolving LXA4 can result in impaired host response to Mycobacterium tuberculosis (Mtb)(4-7). The purpose of this study is to identify host biomarkers associated with TB treatment responses by assessing the plasma lipidome.


In this study, we will assess whether the baseline and early treatment levels and balance of various pro-inflammatory and pro-resolving lipid mediators can predict 1) TB treatment failure and 2) TB recurrence using biobanked samples from a well-characterized cohort of TB cases, funded by the US NIH and Indian government known as the CTRIUMPH RePORT India cohort. Using a longitudinal analysis approach of biobanked samples, we will also assess how these lipid mediators change with treatment and whether the changes are predictive of treatment failure and recurrence. 


  1. Identify lipidome profiles associated with treatment failure or death in adult pulmonary TB patients 

  2. Identify lipidome profiles associated with TB recurrence in cured adult pulmonary TB patients


William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK